Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15168736 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2ARFFAR4ALOX15TP53 | |
| SCHEMBL1702851 | 0.85 | AR (0.45) | SMN1; SMN2ARALDH1A1 | |
| SCHEMBL1702847 | 0.85 | AR (0.45) | SMN1; SMN2ARALDH1A1 | |
| SCHEMBL30436667 | 0.84 | AR (0.50) | SMN1; SMN2ARFFAR4ALOX15CYP3A4 | |
| SCHEMBL524307 | 0.84 | AR (0.50) | SMN1; SMN2ARFFAR4ALOX15CYP3A4 | |
| SCHEMBL1702996 | 0.81 | AR (0.42) | SMN1; SMN2ARALOX15ALDH1A1HSD17B10 | |
| SCHEMBL1702993 | 0.81 | AR (0.42) | SMN1; SMN2ARALOX15ALDH1A1HSD17B10 | |
| SCHEMBL1703049 | 0.80 | AR (0.42) | SMN1; SMN2ARFFAR4 | |
| SCHEMBL1703045 | 0.80 | AR (0.42) | SMN1; SMN2ARFFAR4 | |
| SCHEMBL1703087 | 0.79 | AR (0.47) | SMN1; SMN2ARFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627627-B1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2627643-B1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | BRISTOL MYERS SQUIBB CO (US) | 2016-11-23 | — | — | EP | disclosed |
| EP-2627643-B1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | BRISTOL MYERS SQUIBB CO (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160326101-A1 | Process for the Synthesis of Chiral Propargylic Alcohols | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-9073817-B2 | Efficient process to induce enantioselectivity in procarbonyl compounds | LAURUS LABS PRIVATE LIMITED (IN) | 2015-07-07 | — | — | US | disclosed |
| US-8969550-B2 | Process for the synthesis of cyclic carbamates | LONZA LTD. (CH) | 2015-03-03 | — | — | US | disclosed |
| US-8957204-B2 | Process for the synthesis of cyclic carbamates | LONZA LTD. (CH) | 2015-02-17 | — | — | US | disclosed |
| EP-2627642-B1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | LONZA AG (CH) | 2014-12-24 | — | — | EP | disclosed |
| US-20130324763-A1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | LONZA LTD (CH) | 2013-12-05 | — | — | US | disclosed |
| US-20130217875-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | LONZA LTD (CH) | 2013-08-22 | — | — | US | disclosed |
| EP-2627627-A1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | Lonza Ltd (CH) | 2013-08-21 | — | — | EP | disclosed |
| EP-2627642-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | Lonza Ltd (CH) | 2013-08-21 | — | — | EP | disclosed |
| US-20130211077-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | LONZA LTD (CH) | 2013-08-15 | — | — | US | disclosed |
| WO-2012048886-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | LONZA LTD (CH) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012048887-A1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | LONZA LTD (CH) | 2012-04-19 | — | — | WO | disclosed |
| US-8080655-B2 | Methods of making efavirenz and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2011-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326101-A1 | Process for the Synthesis of Chiral Propargylic Alcohols | ADH1C, ADH1A, ADH5 | SMN1; SMN2 4515/4885AR 3033/4885FFAR4 1388/4885 |
| US-20130217875-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | PLCG2, PLCG1, CPS1 | SMN1; SMN2 4869/4885AR 3636/4885FFAR4 3591/4885 |
| US-20130324763-A1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | ADH1C, ADH1A, ADH5 | SMN1; SMN2 4515/4885AR 3033/4885FFAR4 1388/4885 |
| US-20130211077-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | PLCG2, PLCG1, PLCB1 | SMN1; SMN2 4825/4885AR 2944/4885FFAR4 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.